News Search Results
Jan 27, 2026, 08:00 ET 스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표
입증했으며 전반적으로 안전하고 내약성이 우수한 것으로 나타났다.제1상 임상시험 파트 C 환자 코호트에서 SKY-0515를 투여받은 환자들은 3개월, 6개월, 9개월 차에 기저치 대비 평균 복합 통합 헌팅턴병 등급 척도(Composite Unified Huntington's Disease Rating Scale, cUHDRS)의 개선을 보였다. 9개월 차 통합 분석에서 확인된 개선 수치는 +0.64점으로, 이는 Enroll-HD 및 TRACK-HD를 활용한 성향 점수 가중치 기준 증상 발현 환자의 9개월 예상 악화 수치인 -0.73점과
More news about: Skyhawk Therapeutics
Jan 26, 2026, 08:30 ET Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
developed for the treatment of tardive dyskinesia. In 2023, the company received FDA approval for valbenazine as a treatment for chorea associated with Huntington's disease. For more information about the Phase 2 study (NBI-1065890-TD2033), visit
More news about: Neurocrine Biosciences, Inc.
Jan 22, 2026, 06:55 ET Huntington Bancshares Incorporated Reports 2025 Fourth-Quarter Earnings
Call / Webcast InformationHuntington's senior management will host an earnings conference call on January 22, 2026, at 9:00 a.m. (Eastern Time). The call may be accessed via a live Internet webcast at the Investor Relations section of Huntington's website,
More news about: Huntington Bancshares Incorporated
Jan 22, 2026, 06:55 ET Cadence Bank Announces Fourth Quarter and Annual 2025 Financial Results
completion of the transaction; the ability to complete the transaction and integration of Huntington and the Company successfully; the dilution caused by Huntington's issuance of additional shares of its capital stock in connection with the transaction; and other factors that may affect the future results of Huntington
More news about: Cadence Bank
Jan 21, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Jan 17, 2026, 11:48 ET Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 15, 2026, 08:30 ET Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S.About Chorea Associated with Huntington's DiseaseHuntington's disease (HD) is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes
More news about: Neurocrine Biosciences, Inc.
Jan 12, 2026, 08:30 ET PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
securities of approximately $1.94 billion as of December 31, 2025End-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington's disease (HD) program:Alignment reached on design of global Phase 3 trial, planned to initiate in H1 2026FDA confirmed
More news about: PTC Therapeutics, Inc.
Jan 08, 2026, 16:46 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 06, 2026, 16:15 ET Huntington Bancshares and Cadence Bank Shareholders Approve Pending Merger
Cadence's shareholders have approved the proposed merger of Cadence into The Huntington National Bank and that Huntington's shareholders have approved the issuance of shares of Huntington's common stock in connection with the proposed merger at their respective special shareholder meetings held today.
More news about: Huntington Bancshares Incorporated
Jan 06, 2026, 16:03 ET Huntington Bancshares Incorporated Announces Fourth Quarter 2025 Earnings Call Details
webcast in the Investor Relations section of Huntington's website or through a dial-in telephone number at (877) 407-8029 or (201) 689-8029; conference ID #13757925.A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will be available
More news about: Huntington Bancshares Incorporated
Jan 06, 2026, 03:30 ET LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington's Disease and other triplet repeat expansion diseases. Huntington's disease is an autosomal dominant neurodegenerative disorder for which there is currently no approved disease modifying
More news about: LoQus23 Therapeutics
Jan 05, 2026, 16:01 ET Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Dec 29, 2025, 21:40 ET QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 23, 2025, 15:30 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 22, 2025, 17:20 ET Huntington Bancshares Incorporated and Cadence Bank Announce Receipt of Required Regulatory Approval for Pending Merger
risks, uncertainties and assumptions that are difficult to assess and are subject to change based on factors which are, in many instances, beyond Huntington's and Cadence's control. While there is no assurance that any list of risks and uncertainties or risk factors is complete, below are certain factors
More news about: Huntington Bancshares Incorporated
Dec 22, 2025, 16:05 ET Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
developed for the treatment of tardive dyskinesia. In 2023, the company received FDA approval for valbenazine as a treatment for chorea associated with Huntington's disease. Neurocrine is developing two next generation VMAT2 inhibitors, led by NBI-1065890 entering Phase 2 development for tardive dyskinesia in
More news about: Neurocrine Biosciences, Inc.
Dec 16, 2025, 20:53 ET QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 16, 2025, 16:01 ET Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
and neuroendocrine disorders. The company's diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Dec 16, 2025, 08:00 ET SCOTTIE SCHEFFLER NAMED TEAM HUNTINGTON AMBASSADOR
the course and in life."Today's announcement reflects Huntington's long-term commitment to the sport. Huntington will introduce additional golf ambassadors in the coming months.The Scheffler partnership strengthens Huntington's expanding sports marketing efforts and supports growth in key
More news about: Huntington National Bank
Dec 15, 2025, 09:30 ET Huntington Bank Appoints Marc Dizard as Chief Investment Officer, Wealth Management
modernizing our investment platform and capabilities, all in support of helping our clients meet their goals."This appointment underscores Huntington's commitment to delivering best-in-class investment solutions and driving growth across its Wealth Management platform.For more information
More news about: Huntington National Bank
Dec 12, 2025, 11:45 ET Huntington Bank Opens Branch in South Euclid
businesses thrive than any other financial institution. Huntington has nearly 350 branches in Ohio, with 129 in Northeast Ohio.The launch reflects Huntington's continued investments to enhance and expand its branch network.In October, Huntington announced plans to acquire Cadence Bank, a regional
More news about: Huntington Bank
Dec 10, 2025, 17:38 ET QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 10, 2025, 17:00 ET Huntington Bancshares Incorporated Decreases Its Prime Rate To 6.75 Percent
Huntington's rate last changed on October 30, 2025, decreasing from 7.25 percent to 7.00 percent. About Huntington Huntington Bancshares
More news about: Huntington Bancshares Incorporated
Dec 09, 2025, 16:01 ET Neurocrine Biosciences to Host R&D Day on December 16
and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.